Clinical Trial

Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

Study acronym: IMPRINT
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study investigates whether a single subcutaneous administration of anti-PD-1 antibody can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with \[89Zr\]crefmirlimab berdoxam PET imaging as an imaging biomarker.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-11; most recent amendment 2024-11-26.
Trial Details
NCT Number NCT06218069
Lead Sponsor Radboud University Medical Center
Collaborators: Pfizer, ImaginAb, Inc., University Hospital Tuebingen
Conditions NSCLC
Enrollment 20 participants
Start Date 2025-02
Primary Completion 2025-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-11-29